Sign In
Buy FENC
$10.30
+0.770 (+8.08%)
At Close: Jun 23, 2026
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
06:00am, Monday, 22'nd Jun 2026
RESEARCH TRIANGLE PARK, N.C., June 22, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today annou
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
06:00am, Monday, 15'th Jun 2026
RESEARCH TRIANGLE PARK, N.C., June 15, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today annou
Fennec Announces Results of Annual Meeting
04:30pm, Wednesday, 10'th Jun 2026
RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy
Adherex Technologies' PEDMARK Push Targets Larger AYA Market After Record Quarter
10:06am, Saturday, 23'rd May 2026
Fennec Pharmaceuticals NASDAQ: FENC executives outlined the company's commercial strategy for PEDMARK, its sodium thiosulfate product used to prevent cisplatin-related hearing loss, during a fireside
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
06:01pm, Thursday, 21'st May 2026
~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK ® (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Monday, 18'th May 2026
RESEARCH TRIANGLE PARK, N.C., May 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announ
Fennec Pharmaceuticals Inc. (FENC) Q1 2026 Earnings Call Transcript
12:20pm, Thursday, 14'th May 2026
Fennec Pharmaceuticals Inc. (FENC) Q1 2026 Earnings Call Transcript
Adherex Technologies Q1 Earnings Call Highlights
11:07am, Thursday, 14'th May 2026
Adherex Technologies NASDAQ: FENC executives said Fennec Pharmaceuticals entered 2026 with stronger commercial momentum for PEDMARK, reporting higher first-quarter sales, positive operating cash flow
Adherex Technologies Inc. (FENC) Beats Q1 Earnings and Revenue Estimates
08:40am, Thursday, 14'th May 2026
Adherex Technologies Inc. (FENC) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.04 per share a ye
Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
06:30am, Thursday, 14'th May 2026
~ Achieved First Quarter 2026 Total Net Revenues of $15.1 Million, Up 73% Year Over Year ~ ~ Field Sales Expansion Showing Early Signs of Positive Results with Record PEDMARK ® Demand in April 2026 ~
Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026
06:36am, Thursday, 07'th May 2026
RESEARCH TRIANGLE PARK, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Compa
FENC Secures Second Consecutive Inclusion in S&P Global Dow Jones Best in Class Emerging Markets Index
08:00am, Wednesday, 06'th May 2026
TAIPEI, May 6, 2026 /PRNewswire/ -- Far Eastern New Century Corporation ("FENC" or "the Company") has once again been selected as a constituent of S&P Global 2026 Dow Jones Best in Class (DJBIC) Emerg
Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center
07:03am, Tuesday, 07'th Apr 2026
~ University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK ® in AYA & Adult Patients with Solid Tumors Receiving Cisplatin ~
Adherex Technologies Inc. (NASDAQ:FENC) Receives Average Rating of “Moderate Buy” from Brokerages
04:42am, Wednesday, 01'st Apr 2026
Adherex Technologies Inc. (NASDAQ: FENC - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the six brokerages that are covering the company, Marketbeat Ratings repo
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:00am, Tuesday, 31'st Mar 2026
RESEARCH TRIANGLE PARK, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today anno
